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Carbohydrate mimicry between Campylobacter jejuni lipooligosaccharides (LOS) and host neural ganglio-
sides plays a crucial role in the pathogenesis of Guillain-Barre´ syndrome (GBS). Campylobacter jejuni LOS may
mimic various gangliosides, which affects the immunogenicity and the type of neurological deficits in GBS
patients. Previous studies have shown the interaction of LOS with sialic acid-specific siglec receptors, although
the functional consequences remain unknown. Cells that express high levels of siglecs include dendritic cells
(DCs), which are crucial for initiation and differentiation of immune responses. We confirm that 2,3-
sialylated GD1a/GM1a mimic and 2,8-sialylated GD1c mimic LOS structures interact with recombinant Sn
and siglec-7, respectively. Although the linkage of the terminal sialic acid of LOS did not regulate expression
of DC maturation markers, it displayed clear opposite expression levels of interleukin-12 (IL-12) and OX40L,
molecules involved in DC-mediated Th cell differentiation. Accordingly, targeting DC-expressed siglec-7 with
2,8-linked sialylated LOS resulted in Th1 responses, whereas Th2 responses were induced by targeting with
LOS containing 2,3-linked sialic acid. Thus, our data demonstrate for the first time that depending on the
sialylated composition of Campylobacter jejuni LOS, specific Th differentiation programs are initiated, possibly
through targeting of distinct DC-expressed siglecs.
Infection with Campylobacter jejuni usually causes uncom-
plicated gastroenteritis; however, in rare cases this infection
can lead to the Guillain-Barre´ syndrome (GBS). GBS is a
postinfectious immune-mediated disorder of the peripheral
nerves and nerve roots. Molecular mimicry between lipooligo-
saccharides (LOS) present on the cell wall of C. jejuni and
gangliosides found in the human nervous system is thought to
play a critical role in the pathogenesis of C. jejuni-related GBS
(2). The terminal glycans of both gangliosides and LOS are
composed of 2,3-linked or 2,8-linked sialic acids. In patients
with C. jejuni-related GBS, cross-reactive antibodies against
these bacterial structures are induced during infection. The
specificity of the antibodies is highly associated with the type of
neurological deficits.
Sialic acids are a wide family of carbohydrates, consisting of
a nine-carbon backbone (4). They are distinguished from other
monosaccharides, which are composed of 5 or 6 carbon sugars.
Sialic acids are often found at the outer ends of surface-ex-
posed oligosaccharide chains attached to proteins and lipids to
provide the oligosaccharide with a negative charge. In addi-
tion, in this terminal position they serve as ligands for lectins to
mediate cell-cell interactions (27). Cst-II has been identified as
the sialyltransferase responsible for the sialylation pattern of
C. jejuni-expressed LOS, acting in a bifunctional manner by
catalyzing the formation of both 2,3- and 2,8-linked sialic
acids (16). Loss of sialic acid expression on LOS by cst-II
mutant strains resulted in lower dendritic cell (DC) activation
and subsequent DC-mediated B cell responses (30). The gan-
glioside mimics of GD1a/GM1a and GD1c expressed by C.
jejuni LOS are both sialylated. Interestingly, the GD1a/GM1a
mimics of C. jejuni LOS that express terminal 2,3-linked sialic
acids are associated with pure motor forms of GBS (25),
whereas GD1c mimics of LOS exposing terminal 2,8-linked
sialic acids are associated with GBS with ophthalmoplegia
(18). Thus, the sialylation pattern of C. jejuni LOS could be an
important pathogen-related factor for the induction of GBS.
Sialic acid-binding Ig-like lectins (siglecs) are the best-char-
acterized I-type lectins involved in the recognition of sialic
acids (3). Siglecs are expressed predominantly on cells of the
immune system (12), whereby different leukocyte subsets ex-
press their own variety of siglecs. Siglecs are categorized into
two subsets, the evolutionarily well-conserved group consisting
of sialoadhesin (Sn, or siglec-1), CD22 (siglec-2), MAG (siglec-
4), and siglec-15 and the rapidly evolving CD33-related siglecs
(siglec-3, -5, -7, -8, -9, -10, -11, -14, and -16) (13). All siglecs
have an unique glycan binding specificity, depending mainly on
the linkage of the sialic acid and the underlying glycan (48).
Siglecs are thought to play a role in both positive and negative
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regulation of immune responses (12, 33). CD33-related siglecs
mainly act as negative immunoregulators via their ITIM mo-
tifs. In contrast, siglec-14, -15, and -16 lack ITIMs and interact
with DAP-12, an ITAM-containing receptor. Sn, on the other
hand, lacks known signaling motifs (13).
Previous studies have demonstrated that inhibitory siglecs
interact with sialylated pathogens such as Neisseria meningitidis
and group B streptococci with the potential to subvert immune
responses (6, 10, 26). LOS of C. jejuni strains mimicking GD1a/
GM1a were shown to interact with Sn (21), whereas siglec-7
bound to LOS structures mimicking gangliosides with terminal
2,8-linked sialic acids such as GD1c (6). Sn has a preference
for clustered oligosaccharides terminating in Neu5Ac2,3Gal
(2,3-sialylated glycans) (13). The CD33-related inhibitory re-
ceptor siglec-7 has an unusual preference for 2,8-disialylated
structures over 2,3- and 2,6-sialylated glycans (5, 49). These
2,8-disialylated epitopes are mainly found on gangliosides
(37).
DCs are professional antigen-presenting cells that are im-
portant for the initiation and differentiation of immune re-
sponses. Like other immune cells, DCs express a variety of
siglecs on their surface, including siglec-7 (48). Sn can be
induced on immature monocyte-derived DCs following expo-
sure to rhinovirus (28), most likely via production of alpha
interferon (IFN-), which is a potent inducer of Sn expression
on monocytes (50). Immature DCs reside in the tissue, where
they sense pathogens. Upon pathogen recognition, DCs mi-
grate to the lymph node, where they arrive as fully mature DCs
to promote the polarization of naïve T cells to T helper 1 (Th1)
cells, T helper 2 (Th2) cells, Th17 cells, or regulatory T cells (7,
14, 42). Classically, Th1 cells are critical for immunity to intra-
cellular organisms, whereas Th2 cells convert immunity to ex-
tracellular pathogens and are the major mediators of class
switching in B cells (34, 51).
Because of their siglec expression and important immune
regulatory role, we hypothesized that different LOS structures
of C. jejuni isolates from GBS patients would differentially
influence human DC biology. We show here that the interac-
tion of DCs with both GD1a/GM1a LOS mimics and GD1c
LOS mimics induced DC maturation to similar levels. How-
ever, the GD1a/GM1a mimic induced a more pronounced Th2
skewing, whereas the GD1c mimic induced DC-mediated Th1
responses. Thus, our data demonstrate for the first time that
the sialylated composition of C. jejuni LOS structures deter-
mines DC-mediated T helper cell polarization in a manner
consistent with siglec-dependent modulation.
MATERIALS AND METHODS
Ethics statement. The study was approved by the VU University Medical
Center, Amsterdam, and the Commissie Wetenschappelijk Onderzoek by writ-
ten consent. Written informed consent was obtained from the healthy donors for
the use of blood samples.
Human dendritic cells. Monocytes were isolated from the blood of healthy
donors (Sanquin, Amsterdam, Netherlands) through Ficoll gradient centrifuga-
tion and positive selection of CD14 cells using magnetic activated cell sorting
(MACS) (Miltenyi Biotec, CA). Isolated monocytes (purity, 99%) were cul-
tured in RPMI 1640 (Invitrogen, Gibco, CA) supplemented with 10% fetal calf
serum (FCS) (BioWhittaker, Walkersville, MD), 1,000 U/ml penicillin (BioWhit-
taker, Walkersville, MD), 1,000 U/ml streptomycin (BioWhittaker, Walkersville,
MD), and 2 mM glutamine (BioWhittaker, Walkersville, MD) in the presence of
interleukin-4 (IL-4) (500 U/ml; Biosource, CA) and granulocyte-macrophage
colony-stimulating factor (GM-CSF) (800 U/ml; Biosource, CA) for 7 days (43).
Anti-DC-SIGN stainings confirmed that 99% of our cells were DCs. Matura-
tion was induced by treatment with 10 ng/ml Escherichia coli lipopolysaccharide
(LPS) (Sigma-Aldrich, MO) for 24 h. In order to cleave off sialic acids from the
cell surface, DCs (5  106/ml) were preincubated with Vibrio cholerae neuramin-
idase (Roche) (2.5  102 U/ml) for 1 h at 37°C in TSM (20 mM Tris-HCl, 150
mM NaCl, 1 mM CaCl2, 1 mM MgCl2) (40). Sialic acid-specific lectin stainings
confirmed complete removal of sialic acids.
Bacterial strains and LOS purification. Four C. jejuni strains (GB2, GB11,
GB16, and GB19) were isolated from different GBS patients as described pre-
viously (21). The strains were cultured as reported previously (21), and LOS was
purified by hot phenol-water extraction as described previously (24). Mutagen-
esis of the cst-II target gene was described previously (17), and the corresponding
cst-II mutants derived from GB11 (Cst-II KO) or derived from GB2 (GB2 Cst-II
KO) express a truncated LOS outer core due to the absence of sialic acids, thus
lacking ganglioside mimicry (46). GB19 LOS was incubated with Vibrio cholerae
neuraminidase (Roche) overnight at 37°C to remove sialic acids, followed by
inactivation of neuraminidase for 30 min at 80°C (GB19 neuraminidase). Puri-
fied LOS yields were determined by silver staining and mass spectrometry
(18, 30).
Siglec-Fc binding. Nunc MaxiSorp 96-well enzyme-linked immunosorbent as-
say (ELISA) plates (Nalge Nunc International, Rochester, NY) were coated
overnight at 4°C with 20 g/ml LOS. As a negative control for siglec binding, the
plates where coated with the nonsialylated sugar GalNAc coupled to polyacryl-
amide (PAA), whereas as a positive control the wells were coated with 2,3-
sialyllactose, 2,6-sialyllactose, and 2,8-linked di-, tri-, or polysialic acid coupled
to polyacrylamide (20 g/ml; Lectinity, Moscow, Russia) in phosphate-buffered
saline (PBS). Wells were blocked for 30 min at 37°C with TSM with 1% bovine
serum albumin (BSA) (Calbiochem). For soluble siglecs to bind their sialylated
ligands, a precomplexed conformation is required; therefore, Sn-Fc and siglec-
7-Fc (10 g/ml) were precomplexed with goat anti-human Fc-peroxidase (PO)
(0.5 g/ml) in TSM with 1% BSA for 60 min. at room temperature. This mixture,
consisting of siglec-Fc proteins complexed with anti-human Fc antibodies, was
added to the wells coated with LOS or control glycans and incubated for 60 min
at room temperature. Tetramethylbenzidine (TMB) substrate was added to the
wells, and binding of the precomplexed siglec-Fc proteins to their ligands was
analyzed by measuring the optical density at 450 nm.
Flow cytometry. For antibody stainings, DCs (5  104/well) were incubated
with 10 g/ml 7D2 (20) (anti-Sn), S7.5A (35) (anti-siglec-7), or phycoerythrin
(PE)-labeled anti-OX40L (BD Biosciences, CA) for 45 min at room temperature
(RT) in PBS with 1% BSA. Cells were washed in PBS, and for siglec stainings the
cells were counterstained with a secondary fluorescein isothiocyanate (FITC)-
labeled goat anti-mouse IgG (Zymed, CA) for 30 min at RT in PBS with 1%
BSA. Stainings were analyzed by flow cytometry (FACSCalibur; BD Biosci-
ences, CA).
For maturation assays, DCs (5  104/well) were incubated with PE-labeled
antibodies against human CD80 (BD Biosciences, CA), CD83 (IOtest, New-
castleton, United Kingdom), and CD86 and MCH II (both from BD Biosciences,
CA) in PBS for 45 min at 4°C. After washing, binding was analyzed by flow
cytometry (FACSCalibur; BD Biosciences, CA).
Glycan binding assay. DCs (5  104/well) were pretreated for 45 min at 37°C
with blocking antibodies to human siglec-7 (clone 7.7a) (35), followed by a
30-min incubation at 37°C with 10 g/ml biotinylated PAA attached to galactose,
2,3-sialyllactose, 2,6-sialyllactose, and di- or tri-linked 2,8-sialic acids (Lec-
tinity, Moscow, Russia) in TSM with 1% BSA. Cells were washed in TSM and
stained with Alexa 488-labeled streptavidin (Invitrogen, CA) for 30 min at 37°C
in TSM with 1% BSA. After washing, binding was analyzed by flow cytometry
(FACSCalibur; BD Biosciences, CA).
TLR4 activation. HEK293-TLR4/MD2 cotransfectants (31) were grown in T75
flasks in RPMI 1640 (Invitrogen, Gibco, CA) supplemented with 10% FCS
(BioWhittaker, Walkersville, MD), 10,000 U/ml penicillin (BioWhittaker, Walk-
ersville, MD), 10,000 U/ml streptomycin (BioWhittaker, Walkersville, MD),
10,000 U/ml glutamine (Sigma-Aldrich, MO), and G418 (1 mg/ml). A total of 105
cells in 100 l RPMI were plated into 96-well flat-bottom plates and stimulated
with LOS for 24 h. E. coli LPS served as positive control for Toll-like receptor 4
(TLR4) activation. Subsequently, supernatants were analyzed for IL-8 produc-
tion by ELISA according to the manufacturer’s guidelines (Biosource, CA).
Real-time PCR. Cells were lysed and mRNA was isolated using an mRNA
Capture kit (Roche, Basel, Switzerland). cDNA was synthesized using the Re-
verse Transcription System kit (Promega, WI) according to the manufacturer’s
guidelines. Oligonucleotides were designed by using the computer software
Primer Express 2.0 (Applied Biosystems) and synthesized by Invitrogen Life
Technologies (Invitrogen, Breda, Netherlands). Real-time PCR analysis was
performed as previously described with the SYBR green method in an ABI
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7900HT sequence detection system (Applied Biosystems), using GAPDH (glyc-
eraldehyde-3-phosphate dehydrogenase) as an endogenous reference (15).
Cytokine ELISA. IL-12p70 ELISA was performed as described previously
(44). In short, monoclonal antibody (MAb) 20C2 was applied overnight to Nunc
MaxiSorp 96-well ELISA plates (Nalge Nunc International, Rochester, NY).
The plates were blocked for 30 min at 37°C with PBS supplemented with 1%
BSA, and the supernatants together with MAb C8.6-biotin (BD biosciences)
were added to the plates. IL-12p70 was detected with a streptavidin-PO conju-
gate, and optical density was measured at 450 nm.
T helper cell differentiation assay. The T helper cell assay was performed as
described before (14). Briefly, monocytes were isolated from healthy blood
donors, and DCs were generated as described before. At day 6, maturation was
induced by culturing the cells with 10 ng/ml LOS for 2 days. At day 8, DCs were
harvested and washed. Maturation of the DCs was tested by flow cytometric
analysis of CD86 expression. DCs (5  103) were incubated with 2  104 naïve
CD4 T cells that were purified from peripheral blood lymphocytes (PBLs) using
MACS isolation (Miltenyi Biotec, CA). At day 5 and day 9, human recombinant
IL-2 (rIL-2) (10 U/ml; Cetus, Emeryville, CA) was added to the culture. At day
14, resting T helper cells were restimulated with phorbol myristate acetate
(PMA) (30 ng/ml; Sigma-Aldrich, MO) and ionomycin (1 g/ml; Sigma-Aldrich)
for 6 h. During the last 5 h, brefeldin A (10 g/ml; Sigma-Aldrich) was present
to enable detection of the intracellular production of IL-4 and IFN- (BD
Biosciences) by flow cytometry (FACSCalibur; BD Biosciences, CA).
Statistics. Significant differences in cytokine expression by DCs activated by
GB11 or GB16 LOS were evaluated by Mann-Whitney U tests, and differences
in secretion of cytokines by DCs were evaluated by unpaired t tests (GraphPad
Prism 4.02; GraphPad Software, San Diego, CA). A P value of 0.05 was
considered significant.
RESULTS
Differential binding of Sn and siglec-7 to sialylated LOS
structures. Recent publications have demonstrated that LOS
with terminal 2,3-linked sialic acid (GB11) could bind to Sn
(21), whereas LOS with terminal 2,8-linked sialic acid inter-
acted with siglec-7 (6); however, the functional consequences
of siglec binding were not evaluated on a cellular level. In this
study, we used GB11, the LOS structure that mimics the gan-
gliosides GD1a/GM1a containing terminal 2,3-linked sialic
acid (Fig. 1A), and GB16, the LOS structure that mimics the
ganglioside GD1c, exposing a terminal 2,8-linked sialic acid
(Fig. 1B) (18). As a control, we used the same LOS glycan
structure from a C. jejuni mutant derived from GB11, which
lacks the terminal sialic acid through deletion of the cst-II gene
(Cst-II KO), coding for the sialyltransferase (17) (Fig. 1C).
First, the sialic acid binding specificities of the Sn-Fc and
siglec-7-Fc proteins were evaluated. Therefore, we analyzed
binding of Sn-Fc and siglec-7-Fc to sialylated or N-acetylgalac-
tosylated glycan PAA probes. Sn-Fc interacted with 2,3-
linked sialic acids (Fig. 2A), whereas siglec-7-Fc bound with
the highest avidity to 2,8-linked di- and trisialic acids (Fig.
2B) and no siglec-Fc binding to the negative control N-acetyl-
galactosamine-conjugated PAA was observed (Fig. 2A and B),
confirming reported Sn and siglec-7 carbohydrate specificities
(36).
Next, we determined the potency of Sn and siglec-7 to in-
teract with the sialylated GB11 and GB16 LOS structures.
Sn-Fc displayed binding only to GB11 carrying 2,3-linked
sialic acid. In contrast, siglec-7-Fc interacted both with GB16
carrying 2,8-linked sialic acid and with GB11, due to low-
affinity interactions with 2,3-linked sialic acids. To assess the
sialic acid requirement for this siglec-glycan interaction, bind-
ing of siglec-Fc to LOS structures without terminal sialic acids
(Cst-II KO) was investigated (29). Neither siglec-Fc protein
bound to the mutant without sialic acid (Fig. 2C). Thus, we
demonstrate that GB11 and GB16 interact specifically with
Sn-Fc or siglec-7-Fc in a sialic acid- and linkage-dependent
manner.
Interaction of C. jejuni sialylated LOS structures with DC-
expressed siglecs. To evaluate whether the differential siglec
FIG. 1. Schematic representation of glycan structures from isolates
from GBS patients and the cst-II KO mutant. (A) GB11 and GB2,
containing terminal 2,3-linked sialic acid and the corresponding gan-
glioside GD1a mimic. (B) GB16 and GB19, containing terminal 2,8-
linked sialic acid and the corresponding ganglioside GD1c mimic.
(C) Cst-II KO, GB2 Cst-II KO, and GB19 neuraminidase, lacking
sialic acid.
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binding of GB11 and GB16 could influence immune responses,
we first analyzed the siglec expression pattern of human DCs,
which are important cells for induction and differentiation of
immune responses. In concordance with the literature, human
immature DCs expressed only siglec-7, whereas Sn was not
expressed by immature DCs (Fig. 2D) (12, 32).
To test the ability of immature DC-expressed siglec-7 to
bind sialylated glycans, the interaction of PAA conjugated with
2,3-linked sialyllactose, 2,6-linked sialyllactose, and 2,8-
linked sialic acids (di- and trisialic acids) with DCs was ana-
lyzed by flow cytometry. N-Acetylgalactosamine (Fig. 2A and
B) was not suitable as a negative control in these cellular assays
because of its ability to bind to the DC-expressed lactin C-type
macrophage galactose-type lectin (MGL). Instead we used ga-
lactose as a negative control since both galactose and N-acetyl-
galactosamine are known substrates of sialyltransferases. It is
well accepted that siglecs expressed on immune cells often
have endogenous cis ligands, resulting in masking of siglecs by
recognition of sialic acids present on the same cell membrane.
Masking of siglecs by endogenous sialic acid ligands generally
results in low binding to sialylated trans-ligands (40). Siglecs
can be unmasked and released from their cis ligands by neur-
aminidase treatment. To release DC-expressed siglecs from
potential cis ligands, DCs were pretreated with neuraminidase
before measurement of sialic acid binding. 2,3-linked sialic
acid and 2,6-linked sialic acid displayed low binding to DCs,
whereas 2,8-linked di- and trisialic acids bound with high
affinity to DCs, suggesting interaction with siglec-7. The bind-
ing of sialylated glycans was clearly augmented when siglecs
were unmasked by neuraminidase treatment. To determine the
contribution of siglec-7 in binding of 2,8-sialylated glycans, as
also present on GB16, siglec-7 on DCs was blocked with a
monoclonal antibody prior to PAA-conjugated glycan incuba-
tion. As expected, binding of 2,8-sialylated glycans was me-
diated exclusively by DC-expressed siglec-7 (Fig. 2E). In addi-
tion, neuraminidase treatment or maturation of DCs with LPS
could not improve the low binding of 2,3-linked sialylated
structures (data not shown).
TLR4 activation and DC maturation by LOS. DC activation
following pathogen recognition is mediated by TLRs (41).
TLR4 recognizes the lipid A moiety of LPS, a glycolipid ex-
pressed on the cell surfaces of Gram-negative bacteria (19)
(45). To investigate the potency of LOS to trigger TLR4, HEK
cells transfected with TLR4 and MD2 were used. As siglecs are
FIG. 2. Sn and siglec-7 have different binding specificities toward
sialylated LOS structures. (A and B) Sn-Fc (A) and siglec-7-Fc
(B) proteins were precomplexed with anti-human-Fc PO and added to
coated PAA-conjugated glycan structures. As a control for the sialic
acid specificity of the siglec-Fc proteins, uncoated wells or GalNAc-
PAA-coated wells were used. Depicted are the relative bindings of
precomplexed siglec-Fc proteins compared to the binding of secondary
antibody alone. (C) Sn-Fc and siglec-7-Fc precomplexed with anti-
human-Fc PO binding to coated GB11 (2,3-linked sialic acid), the
Cst-II mutant (without sialic acid), and GB16 (2,8-linked sialic acid)
LOS. (D) Fluorescence-activated cell sorter (FACS) analysis of imma-
ture DCs (thin lines) and mature DCs (bold lines) stained with MAb
7D2 (anti-Sn, left) or MAb S7.5A (anti-siglec-7, right). Dotted lines
are for the corresponding negative controls. (E) Binding of biotin-
ylated glycosylated PAA-conjugated probes to immature DCs as
measured by flow cytometry. Binding to nontreated DCs (medium),
neuraminidase-pretreated DCs (gray bars), or neuraminidase- and
anti-siglec-7-pretreated DCs (black bars) of one representative donor
is depicted. The percentage of cells binding the PAA-glycoconjugates
is depicted. For all experiments, results from one out of five represen-
tative experiments are shown.
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expressed exclusively on leukocytes and in the nervous system,
it is generally accepted that HEK cells do not express siglecs.
Furthermore, HEK cells are not able to bind sialylated glycans
(23). After overnight incubation with LOS, IL-8 levels, corre-
sponding to TLR4 activation, were analyzed. Both GB11 and
GB16 showed high TLR4 activation, comparable to that with
the control LPS of E. coli. Compared to GB11, the lowered
capacity of GB16 to induce IL-8 production after TLR4 en-
gagement may indicate that the sialic acid linkage affects the
ability to trigger TLR4 activation. The Cst-II KO sialic acid
mutant, lacking sialic acids, clearly showed a reduced capacity
to trigger TLR4 (Fig. 3A). This corresponds with our previous
results showing that TLR4-mediated sensing of C. jejuni by
DCs is determined by sialylation (30). Differential effects on
TLR4 triggering could not be due to variations in the lipid A
moiety, since no apparent differences in the lipid A composi-
tions of the C. jejuni strains used in this study were found by
mass spectrometry. TLR4 activation can be modulated by gly-
can binding to lectins expressed by immature DCs (47). To test
if maturation induction of immature DCs is influenced by
differently linked sialic acids expressed on LOS, we measured
the expression levels of maturation markers CD80, CD83,
CD86, and MHCII after overnight incubation of immature
DCs with LOS. E. coli LPS was used as a positive control. For
all LOS concentrations, GB11 and GB16 induced similar ex-
pression levels of markers associated with DC maturation,
indicating that the type of linkage of sialic acid, i.e., 2,3 or
2,8 linked, did not influence DC maturation (Fig. 3B to E).
These data suggest that the presence of sialic acid as well as the
linkage could modulate TLR4 activation; however, both sial-
ylated strains induced DC maturation to similar extents. These
results indicate that sialylated LOS-induced maturation is
partly independent of TLR4.
Sialic acid linkage of LOS influences the cytokine profile of
DCs. To obtain more information about the functional conse-
quences of DC interactions with differentially sialylated LOS
structures, we analyzed expression levels of IL-12p40/70 and
OX40L, which are molecules linked to functional T helper 1
and T helper 2 cell polarization, respectively (14). DCs were
incubated with E. coli LPS or LOS structures of GB11, the
Cst-II mutant, and GB16 for 6 h, and mRNA levels of IL-12p40
were analyzed. The proinflammatory Th1-skewing cytokine IL-
12p40 was strongly upregulated in DCs incubated with GB16
(Fig. 4A). Interestingly, the strong TLR4-activating GB11 dis-
played the lowest IL-12p40 response. These results were con-
firmed by ELISA, in which DCs incubated with GB16 secreted
larger amounts of the Th1-skewing cytokine IL-12p70 than
DCs incubated with GB11 (Fig. 4B). In contrast to this, the
FIG. 3. LOS induces DC maturation and TLR4 activation. (A) TLR4- and MD2-transfected HEK cells were triggered with 1, 10, or 100 ng/ml
LOS or E. coli LPS for 16 h. TLR4 activation was determined by analyzing the IL-8 concentration in the supernatant by ELISA. DCs were
incubated overnight with indicated concentrations of LOS or E. coli LPS. (B to E) The levels of the costimulatory molecules CD80 (B), CD83 (C),
CD86 (D), and MHCII (E) expressed on DCs were measured by FACS analysis. The average mean fluorescence intensity for four donors is shown.
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Th2-polarizing molecule OX40L was expressed at the highest
level on DCs incubated with GB11 and was expressed at low
levels on DCs incubated with GB16, as shown by RT-PCR
(Fig. 4C) and flow cytometry (Fig. 4D). Together, these results
predict that sialic acids present on GB11 and GB16 have dif-
ferential effects on key molecules involved in DC-mediated T
helper cell differentiation.
T helper cell differentiation by LOS-activated DCs is depen-
dent on sialic acid linkage. The clearly regulated expression of
OX40L and IL-12p40/70 by DCs incubated with LOS suggests
that the LOS structures carrying different linkages of the sialic
acids which target specific siglecs would distinctly affect T
helper differentiation. We therefore performed a DC-T cell
coculture assay and measured by flow cytometry at day 14 the
production of IFN- (Th1) and IL-4 (Th2) cytokines by CD4-
positive T cells. As expected by the upregulation of OX40L,
the 2,3-linked sialylated LOS structure GB11 induced a more
pronounced Th2 response, which shifted toward Th1 differ-
entiation when sialic acids were not present due to the
mutation in the sialyltransferase gene (Cst-II KO). Surpris-
ingly, not only the mutant but the siglec-7 binding 2,8-
linked sialylated LOS structure GB16 induced a Th1 re-
sponse as well, indicating that the differently linked sialic
acid structures indeed induced opposite DC T helper cell
differentiation, likely mediated via DC-expressed siglecs
(Fig. 5A). We observed identical T helper profiles with
related LOS structures from GB2 (similar to GB11 with
terminal 2,3-linked sialic acid), GB19 (similar to GB16
with terminal 2,8-linked sialic acid) (18), and their corre-
sponding structures without sialic acids (GB2 Cst-II KO and
GB19 neuraminidase) (Fig. 5B). The T helper differentia-
tion is in concordance with the cytokine expression data. In
contrast, T helper polarization did not reflect the TLR4
activation, in which at the concentration of 10 ng/ml as used
in the T helper differentiation assay, GB11 and GB16
showed higher TLR4 activation than LPS and Cst-II KO. In
conclusion, GB16 induced a distinct T helper differentiation
FIG. 4. IL-12 and OX40L expression levels of DCs are dependent
on sialic acid linkage of LOS. (A and C) To analyze mRNA expression
levels, DCs were incubated with 100 ng/ml LPS, GB11, the Cst-II
mutant, or GB16 for 6 h. Cells were lysed, and the expression of the
Th1-related cytokine IL-12p40 (A) or the Th2-related molecule
OX40L (C) were analyzed by real-time PCR. *, P  0.05. (B and D)
To measure IL-12p70 and OX40L expression at the protein level, DCs
were incubated for 24 h with LPS, GB11, the Cst-II mutant, or GB16.
(B) The secretion of Th1-related cytokine IL-12p70 was analyzed by
ELISA. *, P  0.05. (D) The expression of the Th2-related molecule
OX40L on DCs was analyzed by flow cytometry (n 	 4).
FIG. 5. T cell polarization by LOS-triggered DCs. LOS-matured
DCs with 10 ng/ml of LPS, GB11, the Cst-II mutant, and GB16 (A) or
DCs matured with 10 ng/ml LPS, GB2, GB2 Cst-II KO, GB19, and
GB19 sialidase (B) were incubated with naïve T cells. After 14 days,
the intracellular IL-4 and IFN- production by T cells was measured by
FACS analysis. Average percentages of positive cells for two donors
are shown.
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program compared to GB11, which is displayed by the fact
that these distinct LOS structures differentially affect
OX40L upregulation and IL12p70 production by DCs.
DISCUSSION
GBS is a postinfectious immune-mediated neuropathology
which is probably induced by carbohydrate mimicry between C.
jejuni LOS and host gangliosides, resulting in a cross-reactivity
antibody response to peripheral nerves. Although GB11 and
GB16 were both isolated from patients with GBS, the clinical
presentations are dissimilar. The specificity of the cross-reac-
tive antibodies found in these patients is highly associated with
the type of neurological deficits, probably explained by the
distribution of the gangliosides and reachability by antibodies
in the human peripheral nervous system.
A recent report was the first to describe the interaction
between human monocyte-derived DCs and C. jejuni (22). In
agreement with our data, this study showed that interaction
with C. jejuni induced upregulation of DC cell surface matu-
ration markers and triggering of NF-
B to stimulate the pro-
duction of cytokines, including IL-12. Furthermore, this study
showed that purified C. jejuni LOS was the major stimulant for
the increased production of cytokines by DCs (22). Similarly,
murine DCs also undergo activation and induce Th1 effector
cell responses against C. jejuni (39). A subsequent study
showed that C. jejuni-induced activation of DCs involved co-
operative signaling through the TLR4-MyD88 and TLR4-
TRIF axis (38). We demonstrated that sialic acid expression by
LOS is required for the induction of an efficient immune re-
sponse by DCs (30). This correlates with earlier studies show-
ing that sialic acids play an important role in DC biology (8, 9).
In addition, it has been shown that LOS with terminal 2,3-
linked sialic acids bind to Sn (21), whereas LOS with terminal
2,8-linked sialic acid bind siglec-7 (6). In this study we have
extended these results by investigating whether the sialylated
LOS structures differentially affect DC maturation and subse-
quent T cell polarization. Dendritic cells express various siglecs
on their surface, including siglec-3, siglec-7, siglec-9, siglec-10,
and siglec-15 (36). Because we were interested in siglec-medi-
ated DC activation by 2,3- and 2,8-sialylated LOS struc-
tures, which have been demonstrated before to bind to Sn and
siglec-7, respectively (6, 21), we measured Sn and siglec-7 ex-
pression on our human monocyte-derived DCs. On immature
DCs we detected siglec-7 expression, whereas Sn was detected
on mature DCs only, as demonstrated previously (28). With
anti-siglec-7 antibodies we could completely block the binding
of 2,8-linked sialylated structures to DCs (Fig. 2E). We could
not detect 2,3-linked sialylated PAA binding to DCs even
after neuraminidase treatment or LPS maturation followed by
neuraminidase treatment. The effect of GB11 on DCs could be
explained by a higher affinity of Sn to GB11 due to composition
of the underlying glycan structure, which is different in GB11
compared to the PAA probe. Furthermore, the lipid A tail of
GB11 is likely required for DC modulation. In addition to our
data (Fig. 2A and C), a recent study confirmed Sn binding to
2,3-sialylated LOS structures (21). However, we were not
able to block GB11-induced DC maturation with anti-Sn an-
tibodies (data not shown), suggesting that GB11 in addition to
Sn may bind other DC-expressed lectins. Since DCs express
more lectins with a binding preference for 2,3-linked sial-
ylated structures, including siglec-9 (36), we cannot exclude
that other DC-expressed lectins are responsible for the GB11-
induced DC activation. Siglec-7 carries an inhibitory ITIM
motif in its cytoplasmic tail. The possibility that LOS binds to
siglec-7 and modulates subsequent cellular signaling needs to
be further determined in future experiments in which phos-
phorylation of the ITIM motif as well as activation of signaling
proteins downstream of siglec-7 could be analyzed. Sn has no
internalization motif, although Sn can mediate endocytosis of
bacteria, possibly in synergy with other receptors (26).
As described previously, the sialic acid binding sites of
siglecs expressed on several cell types are masked by endoge-
nous ligands (40). Likewise, we found low binding of sialylated
PAA structures to untreated DCs, whereas upon neuramini-
dase treatment, high binding of sialylated PAA structures was
observed. When non-neuraminidase-treated DCs were incu-
bated with GB16, we did find a Th1-skewed phenotype of DCs
and a subsequent Th1 response, suggesting abolishment of the
cis interactions of siglec-7 with its ligand. The incubation of
2,8-sialylated PAA glycans could not abolish this cis interac-
tion (Fig. 2E), indicating that the conformation of the sialic
acid with its underlying glycan and protein is not strong enough
to compete for sialylated cis ligands. In contrast, the underlying
glycan structure in combination with the lipid A part of GB16
LOS could be a better competitor and thus induce trans inter-
actions with siglec-7. In vivo, unmasking of DC-expressed
siglecs can occur when sialic acids on bacteria outcompete cis
interactions to mediate trans recognition, depending on avidity
effects. In addition, other mechanisms could be involved in
disrupting the cis interactions of siglec-7, such as binding of the
LOS lipid A moiety to TLR4 to serve as a scaffold to recruit
siglec-7. In a wide range of bacteria, intrinsic sialidase activity
has been described, especially in strains isolated from various
infections (11). Likewise, C. jejuni might possess sialidase ac-
tivity and thereby unmask DC-expressed siglecs to create their
own binding sites and thus modulate DC function.
Although C. jejuni binding to siglecs has been observed in
previous studies, the effects of these interactions on immune re-
sponses are poorly understood. As DCs are siglec-expressing cells
which can be programmed to promote Th1 responses or Th2
responses, we investigated the interaction of C. jejuni-expressed
LOS with DCs for subsequent T cell polarization. Interestingly,
we found that activation of DCs with GB11, targeting lectins that
bind 2,3-linked sialic acids, induced Th2 skewing. In contrast,
targeting 2,8-linked sialic acid binding siglecs or lectins capable
of binding galactose with unsialylated LOS induced Th1 skewing.
Unfortunately, we were not able to inhibit cytokine and T helper
responses by adding siglec-7 blocking antibody in our assays. The
antibody was suitable only for blocking binding assays (Fig. 2E),
as it worked in an agonistic manner in cellular assays, causing
siglec-7 signaling. The T helper skewing could help to explain the
differences in pathological conditions observed between patients
after infection with LOS structures mimicking GD1a/GM1a gan-
gliosides (GB11) or with LOS structures mimicking GD1c gan-
gliosides (GB16), as the nature of the T helper response deter-
mines the class switching in mature B cells and thus the isotype of
the antibodies produced. We used highly purified LOS, so it is
unlikely that our LOS preparations contain contaminants that
could trigger other pattern recognition receptors (PRRs) on DCs.
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In addition, we found that TLR2 (data not shown) and TLR4
(Fig. 3A) activation by the sialylated LOS structures did not
reflect the T cell polarization data. This finding was in agreement
with a study by Al-Sayeqh et al. in which they showed that C.
jejuni activates NF-
B independently of TLR4 (1).
In conclusion, we found that the molecules IL-12 and
OX40L, which are involved in DC-mediated Th differentiation,
displayed clear opposite expression levels when 2,3- and 2,8-
linked sialylated LOS structures were compared. Accordingly,
GB11 with 2,3-linked sialic acid promoted Th2 responses,
whereas the LOS structure GB16, with 2,8-linked terminal
sialic acid, induced a Th1 response. Together, these data indi-
cate that besides the presence of cross-reactive antibodies, the
glycan structure of LOS and especially the linkage of the ter-
minal sialic acid may affect the functional properties of DCs in
T cell polarization and could thus contribute to the different
mechanisms of disease involved in GBS.
ACKNOWLEDGMENTS
We thank A. J. van Beelen for helpful suggestions.
This work was supported by V-ICI Ph.D. student grant 2005, by an
Mrace grant from Erasmus MC, by the Netherlands Organization for
Health Research and Development (NWO) (TOP-grant 9120.6150,
NWO-VENI 863.08.020), and by MS Research Stichting 05-598.
REFERENCES
1. Al-Sayeqh, A. F., M. F. Loughlin, E. Dillon, K. H. Mellits, and I. F. Con-
nerton. 2010. Campylobacter jejuni activates NF-kappaB independently of
TLR2, TLR4, Nod1 and Nod2 receptors. Microb. Pathog. 49:294–304.
2. Ang, C. W., B. C. Jacobs, and J. D. Laman. 2004. The Guillain-Barre
syndrome: a true case of molecular mimicry. Trends Immunol. 25:61–66.
3. Angata, T., and E. Brinkman-Van der Linden. 2002. I-type lectins. Biochim.
Biophys. Acta 1572:294–316.
4. Angata, T., and A. Varki. 2002. Chemical diversity in the sialic acids and
related alpha-keto acids: an evolutionary perspective. Chem. Rev. 102:439–
469.
5. Avril, T., H. Floyd, F. Lopez, E. Vivier, and P. R. Crocker. 2004. The
membrane-proximal immunoreceptor tyrosine-based inhibitory motif is crit-
ical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related
Siglecs expressed on human monocytes and NK cells. J. Immunol. 173:6841–
6849.
6. Avril, T., E. R. Wagner, H. J. Willison, and P. R. Crocker. 2006. Sialic
acid-binding immunoglobulin-like lectin 7 mediates selective recognition of
sialylated glycans expressed on Campylobacter jejuni lipooligosaccharides.
Infect. Immun. 74:4133–4141.
7. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of
immunity. Nature 392:245–252.
8. Bax, M., et al. 2007. Dendritic cell maturation results in pronounced changes
in glycan expression affecting recognition by siglecs and galectins. J. Immu-
nol. 179:8216–8224.
9. Bax, M., S. J. van Vliet, M. Litjens, J. J. Garcia-Vallejo, and Y. van Kooyk.
2009. Interaction of polysialic acid with CCL21 regulates the migratory
capacity of human dendritic cells. PLoS One 4:e6987.
10. Carlin, A. F., A. L. Lewis, A. Varki, and V. Nizet. 2007. Group B strepto-
coccal capsular sialic acids interact with siglecs (immunoglobulin-like lectins)
on human leukocytes. J. Bacteriol. 189:1231–1237.
11. Corfield, T. 1992. Bacterial sialidases—roles in pathogenicity and nutrition.
Glycobiology 2:509–521.
12. Crocker, P. R., J. C. Paulson, and A. Varki. 2007. Siglecs and their roles in
the immune system. Nat. Rev. Immunol. 7:255–266.
13. Crocker, P. R., and P. Redelinghuys. 2008. Siglecs as positive and negative
regulators of the immune system. Biochem. Soc. Trans. 36:1467–1471.
14. de Jong, E. C., et al. 2002. Microbial compounds selectively induce Th1
cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse Th
cell-polarizing signals. J. Immunol. 168:1704–1709.
15. Garcia-Vallejo, J. J., et al. 2004. Approach for defining endogenous
reference genes in gene expression experiments. Anal. Biochem. 329:293–
299.
16. Gilbert, M., et al. 2000. Biosynthesis of ganglioside mimics in Campylo-
bacter jejuni OH4384. Identification of the glycosyltransferase genes,
enzymatic synthesis of model compounds, and characterization of nano-
mole amounts by 600-mhz (1)h and (13)c NMR analysis. J. Biol. Chem.
275:3896–3906.
17. Godschalk, P. C., et al. 2004. The crucial role of Campylobacter jejuni genes
in anti-ganglioside antibody induction in Guillain-Barre syndrome. J. Clin.
Invest. 114:1659–1665.
18. Godschalk, P. C., et al. 2007. Structural characterization of Campylobacter
jejuni lipooligosaccharide outer cores associated with Guillain-Barre and
Miller Fisher syndromes. Infect. Immun. 75:1245–1254.
19. Hargreaves, D. C., and R. Medzhitov. 2005. Innate sensors of microbial
infection. J. Clin. Immunol. 25:503–510.
20. Hartnell, A., et al. 2001. Characterization of human sialoadhesin, a sialic acid
binding receptor expressed by resident and inflammatory macrophage pop-
ulations. Blood 97:288–296.
21. Heikema, A. P., et al. 2010. Characterization of the specific interaction
between sialoadhesin and sialylated Campylobacter jejuni lipooligosaccha-
rides. Infect. Immun. 78:3237–3246.
22. Hu, L., M. D. Bray, M. Osorio, and D. J. Kopecko. 2006. Campylobacter
jejuni induces maturation and cytokine production in human dendritic cells.
Infect. Immun. 74:2697–2705.
23. Hudson, S. A., N. V. Bovin, R. L. Schnaar, P. R. Crocker, and B. S. Bochner.
2009. Eosinophil-selective binding and proapoptotic effect in vitro of a syn-
thetic Siglec-8 ligand, polymeric 6-sulfated sialyl Lewis x. J. Pharmacol. Exp.
Ther. 330:608–612.
24. Jacobs, B. C., M. P. Hazenberg, P. A. van Doorn, H. P. Endtz, and F. G.
van der Meche. 1997. Cross-reactive antibodies against gangliosides and
Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barre or
Miller Fisher syndrome. J. Infect. Dis. 175:729–733.
25. Jacobs, B. C., et al. 1996. Campylobacter jejuni infections and anti-GM1
antibodies in Guillain-Barre syndrome. Ann. Neurol. 40:181–187.
26. Jones, C., M. Virji, and P. R. Crocker. 2003. Recognition of sialylated
meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads
to enhanced bacterial uptake. Mol. Microbiol. 49:1213–1225.
27. Kelm, S., and R. Schauer. 1997. Sialic acids in molecular and cellular inter-
actions. Int. Rev. Cytol. 175:137–240.
28. Kirchberger, S., et al. 2005. Human rhinoviruses inhibit the accessory func-
tion of dendritic cells by inducing sialoadhesin and B7-H1 expression. J. Im-
munol. 175:1145–1152.
29. Koga, M., M. Takahashi, M. Masuda, K. Hirata, and N. Yuki. 2005.
Campylobacter gene polymorphism as a determinant of clinical features of
Guillain-Barre syndrome. Neurology 65:1376–1381.
30. Kuijf, M. L., et al. 2010. TLR4-mediated sensing of Campylobacter jejuni by
dendritic cells is determined by sialylation. J. Immunol. 185:748–755.
31. Latz, E., et al. 2002. Lipopolysaccharide rapidly traffics to and from the Golgi
apparatus with the Toll-like receptor 4-MD-2-CD14 complex in a process
that is distinct from the initiation of signal transduction. J. Biol. Chem.
277:47834–47843.
32. Lock, K., J. Zhang, J. Lu, S. H. Lee, and P. R. Crocker. 2004. Expression of
CD33-related siglecs on human mononuclear phagocytes, monocyte-derived
dendritic cells and plasmacytoid dendritic cells. Immunobiology. 209:199–
207.
33. McMillan, S. J., and P. R. Crocker. 2008. CD33-related sialic-acid-binding
immunoglobulin-like lectins in health and disease. Carbohydr. Res. 343:
2050–2056.
34. Mosmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: different
patterns of lymphokine secretion lead to different functional properties.
Annu. Rev. Immunol. 7:145–173.
35. Nicoll, G., et al. 1999. Identification and characterization of a novel siglec,
siglec-7, expressed by human natural killer cells and monocytes. J. Biol.
Chem. 274:34089–34095.
36. O’Reilly, M. K., and J. C. Paulson. 2009. Siglecs as targets for therapy in
immune-cell-mediated disease. Trends Pharmacol. Sci. 30:240–248.
37. Rapoport, E., I. Mikhalyov, J. Zhang, P. Crocker, and N. Bovin. 2003.
Ganglioside binding pattern of CD33-related siglecs. Bioorg. Med. Chem.
Lett. 13:675–678.
38. Rathinam, V. A., D. M. Appledorn, K. A. Hoag, A. Amalfitano, and L. S.
Mansfield. 2009. Campylobacter jejuni-induced activation of dendritic cells
involves cooperative signaling through Toll-like receptor 4 (TLR4)-MyD88
and TLR4-TRIF axes. Infect. Immun. 77:2499–2507.
39. Rathinam, V. A., K. A. Hoag, and L. S. Mansfield. 2008. Dendritic cells from
C57BL/6 mice undergo activation and induce Th1-effector cell responses
against Campylobacter jejuni. Microbes Infect. 10:1316–1324.
40. Razi, N., and A. Varki. 1999. Cryptic sialic acid binding lectins on human
blood leukocytes can be unmasked by sialidase treatment or cellular activa-
tion. Glycobiology 9:1225–1234.
41. Reis e Sousa, C. 2004. Toll-like receptors and dendritic cells: for whom the
bug tolls. Semin. Immunol. 16:27–34.
42. Reis e Sousa, C. 2006. Dendritic cells in a mature age. Nat. Rev. Immunol.
6:476–483.
43. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble
antigen by cultured human dendritic cells is maintained by granulocyte/
macrophage colony-stimulating factor plus interleukin 4 and downregulated
by tumor necrosis factor alpha. J. Exp. Med. 179:1109–1118.
44. Snijders, A., et al. 1996. Regulation of bioactive IL-12 production in lipo-
2688 BAX ET AL. INFECT. IMMUN.
polysaccharide-stimulated human monocytes is determined by the expres-
sion of the p35 subunit. J. Immunol. 156:1207–1212.
45. Trent, M. S., C. M. Stead, A. X. Tran, and J. V. Hankins. 2006. Diversity of
endotoxin and its impact on pathogenesis. J. Endotoxin Res. 12:205–223.
46. Van Belkum, A., et al. 2001. A Campylobacter jejuni gene associated with
immune-mediated neuropathy. Nat. Med. 7:752–753.
47. van Vliet, S. J., J. J. Garcia-Vallejo, and Y. van Kooyk. 2008. Dendritic cells
and C-type lectin receptors: coupling innate to adaptive immune responses.
Immunol. Cell Biol. 86:580–587.
48. Varki, A., and T. Angata. 2006. Siglecs—the major subfamily of I-type lec-
tins. Glycobiology 16:1R–27R.
49. Yamaji, T., T. Teranishi, M. S. Alphey, P. R. Crocker, and Y. Hashimoto.
2002. A small region of the natural killer cell receptor, Siglec-7, is re-
sponsible for its preferred binding to alpha 2,8-disialyl and branched
alpha 2,6-sialyl residues. A comparison with Siglec-9. J. Biol. Chem.
277:6324–6332.
50. York, M. R., et al. 2007. A macrophage marker, Siglec-1, is increased on
circulating monocytes in patients with systemic sclerosis and induced by type
I interferons and Toll-like receptor agonists. Arthritis Rheum. 56:1010–1020.
51. Zhu, J., and W. E. Paul. 2008. CD4 T cells: fates, functions, and faults. Blood
112:1557–1569.
Editor: S. R. Blanke
VOL. 79, 2011 C. JEJUNI LOS MODULATE DC-MEDIATED T CELL POLARIZATION 2689
